Research programme: enterotoxigenic Escherichia coli vaccine - Abera Bioscience
Latest Information Update: 30 Jun 2023
At a glance
- Originator Abera Bioscience AB
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Escherichia coli infections
Most Recent Events
- 21 Jun 2023 Research programme: enterotoxigenic Escherichia coli vaccine - Abera Bioscience is available for licensing as of 21 Jun 2023. https://aberabio.com/partnering-licensing/
- 21 Jun 2023 Preclinical trials in Escherichia coli infections (Prevention) in Sweden (unspecified route) (Abera Bioscience pipeline, June 2023)